Celldex Therapeutics, Inc. — Q1 2013 Form 10-Q
Business context and period. Unaudited results for the three months ended March 31, 2013, compared with Q1 2012. Celldex is a clinical-stage biopharmaceutical company developing immunotherapies and antibody-drug conjugates. Its lead programs include rindopepimut for glioblastoma and CDX-011 for breast cancer; the company had no meaningful product sales and relied primarily on royalties and financing.
Financial results and liquidity
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Total revenue | $2.414 million | $2.433 million, down 1% |
| Research and development expense | $14.090 million | $10.769 million, up 31% |
| General and administrative expense | $3.138 million | $2.317 million, up 35% |
| Operating loss | $17.401 million | $13.288 million |
| Net loss | $17.332 million; $0.23 per share | $13.516 million; $0.27 per share |
| Net cash used in operating activities | $17.200 million | $13.553 million |
All financial amounts above are in U.S. dollars. Revenue was largely $2.334 million of Rotarix royalties, matched by the same amount of royalty expense payable to Cincinnati Children’s Hospital Medical Center; Celldex said these royalties were expected to end during 2013. The filing does not present a conventional positive operating margin: operating expenses substantially exceeded revenue.
At March 31, 2013, cash and cash equivalents were $75.627 million and marketable securities were $106.750 million, totaling approximately $182.4 million. Working capital was $166.1 million. Total liabilities were $29.4 million; term-loan principal was approximately $10.1 million, with a minimum annual interest rate of 9.5% and maturity in December 2014. The loan is secured by substantially all assets other than intellectual property; management reported compliance with its covenants.
Net cash provided by financing was $114.5 million, chiefly from stock issuances. Celldex raised $97.0 million net in a February 2013 public offering and $17.1 million net through its Cantor equity program. Shares outstanding rose to 80.9 million from 64.4 million at year-end 2012. Investing activities used $46.6 million, primarily reflecting purchases of marketable securities. The company reported no material market-risk exposure from its short-term investment portfolio.
Material changes and operating developments
- Net loss increased by $3.8 million year over year, mainly because R&D and G&A costs rose. Rindopepimut was the largest disclosed R&D program expense: $8.9 million versus $4.9 million in Q1 2012. Management expected R&D, operating cash use, and G&A to increase over the next twelve months, primarily to support rindopepimut and CDX-011 development and commercial planning.
- Celldex said its Q1-end cash and securities would fund planned operations through 2015; the financial-statement note separately states resources were sufficient for at least the next twelve months. Management also said it might seek further financing, licensing, or collaborations for longer-term needs.
- The FDA removed the partial clinical hold on CDX-011 in March 2013 after reviewing the company’s response concerning product reprocessing. The hold had followed cGMP violations at a contract manufacturer.
- Rotarix royalty revenue and the corresponding royalty expense were expected to end during 2013 following expiration of a U.S. patent; a Mexican patent application was the remaining relevant patent right described.
Outlook, commentary, and risks
- Celldex expected ACT IV, its pivotal Phase 3 rindopepimut trial, to complete enrollment by year-end 2013, with data anticipated 18–24 months after enrollment completion. The company estimated the trial would cost more than $60 million over its duration.
- Data from the ReACT Phase 2 rindopepimut study were expected in the second half of 2013. Celldex planned to initiate a randomized CDX-011 study in GPNMB-overexpressing triple-negative breast cancer in the second half of 2013, subject to development progress.
- Management anticipated a CDX-1135 pilot-study update by year-end 2013, CDX-1127 data in the second half of 2013, and a CDX-301 pilot study in stem-cell transplantation in the second half of 2013. These are forward-looking expectations, not guaranteed outcomes.
- Principal risks include clinical-trial safety and efficacy results, regulatory approval and trial timing, manufacturing and clinical-service availability, intellectual-property disputes, and the ability to finance development. Failure to raise capital on acceptable terms could require delays or discontinuation of programs, unfavorable licensing or financing, or sale of some or all of the business. Further equity issuance may dilute shareholders; debt could add payment obligations and restrictive covenants.
- A May 1, 2013 lease, subsequent to quarter-end, covers approximately 33,000 square feet in New Jersey. The five-year, five-month term is expected to begin no earlier than November 15, 2013 (subject to completion of alterations and occupancy approval); annual rent rises from $0.4 million to $0.5 million, with two five-year renewal options.
Important facts for investors to verify
- Whether ACT IV accrual and anticipated data timing remain on track, and whether the planned trial spending fits the company’s cash runway.
- Whether CDX-011’s reported subgroup results translate into a successful follow-on study, and the implications of the manufacturing-related hold and its removal.
- How the stated runway through 2015 compares with the financial-statement note’s shorter “at least twelve months” assessment, given expected increases in development spending.
- The end date and continuing value of Rotarix royalties, and whether any extension or replacement collaboration is secured.
- The effects of the 2013 share issuances on dilution, and the term-loan repayment schedule, fees, collateral, and covenant compliance.